Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Moodys
AstraZeneca
Merck
McKinsey

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

ENBREL MINI Drug Profile


Email this page to a colleague

« Back to Dashboard

Summary for Tradename: ENBREL MINI
Patents:0
Applicants:1
BLAs:1
Drug Prices: Drug price information for ENBREL MINI
Pharmacology for ENBREL MINI
Mechanism of ActionTumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic ClassTumor Necrosis Factor Blocker
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENBREL MINI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENBREL MINI Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Immunex Corporation ENBREL MINI etanercept Injection 103795 ⤷  Free Forever Trial 2012-03-07 Company disclosures
Immunex Corporation ENBREL MINI etanercept Injection 103795 ⤷  Free Forever Trial 2014-02-25 Company disclosures
Immunex Corporation ENBREL MINI etanercept Injection 103795 ⤷  Free Forever Trial 2009-09-05 Company disclosures
Immunex Corporation ENBREL MINI etanercept Injection 103795 ⤷  Free Forever Trial 2009-09-11 Company disclosures
Immunex Corporation ENBREL MINI etanercept Injection 103795 ⤷  Free Forever Trial 2009-09-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for ENBREL MINI Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for ENBREL MINI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 15/2000 Austria ⤷  Free Forever Trial PRODUCT NAME: ETANERCEPT
SPC/GB00/015 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: ETANERCEPT; REGISTERED: CH 55365 20000201; UK EU/1/99/126/001 20000203
0090011-8, 0091011-7 Sweden ⤷  Free Forever Trial NATIONAL REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
C300008 Netherlands ⤷  Free Forever Trial PRODUCT: ETANERCEPTUM
15/2000 Austria ⤷  Free Forever Trial PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Mallinckrodt
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.